Assembly Biosciences, Inc. ASMB
20.18 USD -2.19 (-9.79%)
At closeNov 12, 2026, 4:20 PM EST
20.18 0.00 0.00%
After hours · Nov 12, 4:20 PM ET
19.84 Day range 22.10
19.51 52-week range 38.50
- YTD
- -40.66%
- 1 year
- -43.71%
News
zacks.com Assembly Biosciences (ASMB) Reports Q3 Loss, Lags Revenue Estimates Assembly Biosciences (ASMB) came out with a quarterly loss of $0.93 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to a loss of $0.72 per share a year ago.
globenewswire.com Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates – Initiated Phase 2 clinical study of ABI-6250 in patients with chronic hepatitis delta virus infection –
benzinga.com UBS Maintains Buy on Assembly Biosciences, Lowers Price Target to $48 UBS analyst Ashwani Verma maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and lowers the price target from $52 to $48.
globenewswire.com Assembly Biosciences to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver…
benzinga.com Assembly Biosciences Doses First Two Patients In Its Phase 2 Clinical Trial Of ABI-6250 To Treat Chronic Hepatitis Delta Virus Infection Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced dosing of the first two participants…
globenewswire.com Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus – Phase 2 study will evaluate the safety, pharmacokinetics and antiviral activity of ABI-6250 in participants with chronic HDV infection – – Initial data from the Phase 2 study is expected in the…
defenseworld.net Analyzing RYTHM (NASDAQ:RYM) and Assembly Biosciences (NASDAQ:ASMB) Assembly Biosciences (NASDAQ: ASMB - Get Free Report) and RYTHM (NASDAQ: RYM - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two…
benzinga.com Assembly Biosciences To Present New Phase 1a Data From Its ABI-6250 Program At The Liver Meeting 2026 Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced that two posters featuring new Phase…
globenewswire.com Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026 ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction
zacks.com Best Momentum Stocks to Buy for September 17th MSGM, ASMB and MTG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 17th, 2026.
zacks.com New Strong Buy Stocks for September 17th MOV, MAX, MTG, ASMB and MSGM have been added to the Zacks Rank #1 (Strong Buy) List on September 17th, 2026.
globenewswire.com Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver…
zacks.com Oil Surge Continues on Escalating Middle East Crisis: 4 Defensive Picks COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.
globenewswire.com Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program – Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes –
zacks.com Wall Street Analysts See a 35.71% Upside in Assembly Biosciences (ASMB): Can the Stock Really Move This High? The average of price targets set by Wall Street analysts indicates a potential upside of 35.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is…
zacks.com Should You Buy Assembly Biosciences (ASMB) After Golden Cross? Assembly Biosciences, Inc. (ASMB) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ASMB's 50-day simple moving average broke out…
zacks.com 5 Stocks With Recent Price Strength Buoyed by a Strong August EDRY, RCMT, ASMB, DCTH and NESR show strong recent price momentum after a strong August, backed by improving earnings expectations.
zacks.com Here's Why Momentum in Assembly Biosciences (ASMB) Should Keep going Assembly Biosciences (ASMB) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
benzinga.com Mizuho Maintains Outperform on Assembly Biosciences, Lowers Price Target to $45 Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and lowers the price target from $53 to $45.
zacks.com Best Momentum Stocks to Buy for August 25th LQDT, IA and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 25th, 2026.
zacks.com New Strong Buy Stocks for August 25th IA, ASMB, LQDT, OFG and TGT have been added to the Zacks Rank #1 (Strong Buy) List on August 25th, 2026.
zacks.com Best Momentum Stocks to Buy for August 21st LITE, ONTO and ASMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 21st, 2026.
zacks.com New Strong Buy Stocks for August 21st MCY, ASMB, ONTO, BSET and UNH have been added to the Zacks Rank #1 (Strong Buy) List on August 21st, 2026.
zacks.com Are You Looking for a Top Momentum Pick? Why Assembly Biosciences (ASMB) is a Great Choice Does Assembly Biosciences (ASMB) have what it takes to be a top stock pick for momentum investors? Let's find out.- benzinga.com HC Wainwright & Co. Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $50 price target.
- benzinga.com Assembly Biosciences Q2 EPS $(0.20) Beats $(0.65) Estimate, Sales $13.374M Beat $8.599M Estimate Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.65) by 69.23 percent. This is a 84.96 percent increase over losses…
benzinga.com Mizuho Maintains Outperform on Assembly Biosciences, Raises Price Target to $45 Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and raises the price target from $40 to $45.
benzinga.com Guggenheim Reiterates Buy on Assembly Biosciences, Maintains $43 Price Target Guggenheim analyst Vamil Divan reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $43 price target.
benzinga.com Crude Oil Edges Higher; US Consumer Sentiment Falls In May US stocks rose, Dow gained over 400 points. S&P 500 and NASDAQ also up. Health care shares jumped, while communication services fell. University of Michigan's consumer sentiment index hit record low.…
benzinga.com Zoom Upbeat Q1 Results, Joins Lionsgate Studios, Ross Stores And Other Big Stocks Moving Higher On Friday Zoom Communications Inc shares rise after strong financial results and increased buyback authorization. Other big gainers include IMRX, INFQ, ASMB, IMAX, RGTI, HLIT, DELL, EL, GSIT, ELVR, and HPQ.- benzinga.com Assembly Biosciences Prices $100M Offering Of 3,358,602 At $26.50 Per Share And Warrants To Purchase Up To 415,000 Shares At Offer Price Of $26.499 Per Pre-Funded Warrant Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced the pricing of an underwritten,…
benzinga.com Assembly Biosciences Announces Plans To Expand Clinical Development Of ABI-6250 Into Primary Biliary Cholangitis And Primary Sclerosing Cholangitis "We are excited to expand the ABI-6250 program into PBC and PSC, where there remains significant unmet medical need despite existing PBC therapies, and in the case of PSC, no approved treatments,"…- benzinga.com Assembly Biosciences Q1 EPS $(0.54) Beats $(0.71) Estimate, Sales $8.213M Miss $9.266M Estimate Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.71) by 23.94 percent. This is a 53.85 percent increase over losses…
benzinga.com HC Wainwright & Co. Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $50 price target.- benzinga.com Assembly Biosciences Presents Phase 1b Data For ABI-5366 And ABI-1179 At ESCMID Global – Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation –– Phase 1b data from ABI-1179 accepted for late-breaker poster presentation –
benzinga.com Guggenheim Maintains Buy on Assembly Biosciences, Raises Price Target to $43 Guggenheim analyst Vamil Divan maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and raises the price target from $39 to $43.- benzinga.com HC Wainwright & Co. Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $50 price target.
benzinga.com Scholastic Posts Upbeat Q3 Earnings, Joins Firefly Aerospace, Arm Holdings And Other Big Stocks Moving Higher On Friday Scholastic Corp (NASDAQ: SCHL) rose 10.7% on Friday after reporting better-than-expected earnings and announcing a $200 million buyback. Other big gainers include Planet Labs PBC (NYSE: PL),…- benzinga.com Assembly Biosciences Q4 EPS $1.30 Beats $(0.65) Estimate, Sales $42.469M Beat $7.423M Estimate Assembly Biosciences (NASDAQ:ASMB) reported quarterly earnings of $1.30 per share which beat the analyst consensus estimate of $(0.65) by 300 percent. This is a 182.8 percent increase over losses of…
benzinga.com Gilead Sciences Bets On Weekly Pill To Tackle Genital Herpes Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activity and weekly oral dosing potential.- benzinga.com HC Wainwright & Co. Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $50 price target.
- benzinga.com Gilead Sciences Exercises Option To License Assembly Bio's Herpes Simplex Virus Helicase-Primase Inhibitor Programs Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (NASDAQ:ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio's herpes simplex virus…
- benzinga.com Mizuho Maintains Outperform on Assembly Biosciences, Raises Price Target to $40 Mizuho analyst Salim Syed maintains Assembly Biosciences (NASDAQ:ASMB) with a Outperform and raises the price target from $29 to $40.
- benzinga.com Assembly Biosciences Q3 EPS $(0.72) Beats $(0.78) Estimate, Sales $10.789M Beat $7.459M Estimate Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.78) by 7.1 percent. This is a 52.32 percent increase over losses of…
- benzinga.com Assembly Biosciences Data From Phase 1b Study Demonstrates ABI-4334 Was Well Tolerated Across Both Dose Levels In Patients With Chronic Hepatitis B Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced Phase 1b clinical data for its next-generation…
- benzinga.com Forecasting The Future: 4 Analyst Projections For Assembly Biosciences
benzinga.com HC Wainwright & Co. Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $50 price target.
benzinga.com 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action.- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session